Renal Tracer Elimination in Thyroid Cancer Patients Treated With 131-Iodine

NCT02773667 | Completed

• 1 other identifier: I-131-07/2015
• Study Type: observational
• Target: 83
• Locations: 1 country
• Sites: 1

Brief Summary

Correlation analysis between estimated renal function and biological half life of 131-I during radioiodine treatment of patients with differentiated thyroid cancer.

Conditions

Thyroid Carcinoma

Outcome Measures

Primary Outcomes (1)

• Correlation between estimated renal function and biological half life of 131-I

  The estimated renal function (estimated GFR) is measured via determination of serum creatinine and Cystatin C. The biological half-life of I-131 is determined via whole-body dosimetry (whole-body probe and whole-body gamma camera) and blood probe measurement. Update 2017/06/07: After analyzing the preliminary results (based on the first 48 patients) probe measurements are not longer needed in a simplified study design. Additionally, measuring the creatinine concentration is no longer needed in comparison to the Cystatin C measurements.

  2 years

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Patients with histological secured differentiated thyroid cancer stationary for treatment or diagnostic with radioiodine

You may qualify if:

• patients with differentiated thyroid carcinoma
• stationary for treatment or diagnostic with radioiodine
• state after thyroidectomy
• written consent of the patient
• minimum age 18 years

You may not qualify if:

• no written consent of the patient
• patients with large residual thyroid tissue (iodine uptake \> 10%)
• children under 18 years of age
• patients without TSH-stimulation by rhTSH

Sponsors & Collaborators

• Jena University Hospital: lead

Study Sites (1)

University Hospital Jena

Jena, Thuringia, 07745, Germany

Location

MeSH Terms

Conditions

Thyroid Neoplasms

Condition Hierarchy (Ancestors)

Endocrine Gland Neoplasms; Neoplasms by Site; Neoplasms; Head and Neck Neoplasms; Endocrine System Diseases; Thyroid Diseases

Study Officials

• Martin Freesmeyer, Dr. med.

  Study Principal Investigator

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: CASE ONLY
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: May 11, 2016
• First Posted: May 16, 2016
• Study Start: January 1, 2016
• Primary Completion: December 1, 2022
• Study Completion: December 1, 2022
• Last Updated: December 16, 2022

Record last verified: 2022-12

Data Sharing

• IPD Sharing: Will not share

Locations

DE (1)